ASX Share rice
Mon 17 May 2021 - 04:17:am (Sydney)

BGT Share Price

BIO-GENE TECHNOLOGY LTDBGTMaterials

BGT Company Information

Name:

Bio-Gene Technology Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Chemicals

GIC Sub Industry:

Fertilizers & Agricultural Chemicals

Address:

456 Lonsdale Street Melbourne VIC Australia 3000

Phone:

61 3 9068 1062

MD, CEO & Director:

Mr. Richard Jagger B.Sc., BSC (HONS), M.INTL.BUS, GAICD

CFO & Company Sec.:

Mr. Roger McPherson C.P.A., CPA, B.Bus, GAICD

Exec. Director of R&D and Exec. Director:

Mr. Peter Donald May AFAIM, M.B.A., MBA, AFA1M, GAICD

Company Overview:

Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

BGT Share Price Information

Shares Issued:

151.61M

Market Capitalisation:

$28.05M

Revenue (TTM):

$82.80K

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.018

Operating Margin (TTM):

$-28.37

Return On Assets (TTM):

$-0.28

Return On Equity (TTM):

$-0.49

Quarterly Revenue Growth (YOY):

-0.5

Gross Profit(TTM):

$-85,895

Diluted Earnings Per Share (TTM):

$-0.017

BGT CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$-180,470

Net Borrowings:

$-13,768

Net Income:

$-1,933,099

Total Cash From Operating Activities:

$-1,644,691

Depreciation:

$58.44K

Change To Account Receivables:

$-10,275

Sale Purchase Of Stock:

$2.83M

Capital Expenditures:

$0

BGT Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-1,933,100

Net Income:

$-1,933,100

Gross Profit:

$0.91M

Operating Income:

$-1,931,870

Other Operating Expenses:

$-561,662

Total Revenue:

$1.04M

BGT Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$350.96K

Total Liabilities:

$567.29K

Total Stockholder Equity:

$6M

Other Current Liabilities:

$54.83K

Total Assets:

$6.57M

Common Stock:

$14.54M

Other Current Assets:

$74.20K

Retained Earnings:

$-9,483,358

Other Liabilities:

$155.28K

Cash:

$5.52M

Total Current Liabilities:

$412.01K

Property - Plant & Equipment:

$36.98K

Net Tangible Assets:

$5.65M

Total Current Assets:

$6.18M

Net Receivables:

$483.04K

Short-Term Investments:

$387.93K

Accounts Payable:

$133.95K

Short-Term Investments:

$387.93

Non Current Liabilities (Other):

$150K

Non Current Liabilities Total:

$155.28K

BGT Share Price History

BGT News

23 Feb, 2021
We feel now is a pretty good time to analyse Bio-Gene Technology Limited's ( ASX:BGT ) business as it appears the...
25 Nov, 2020
Richard Jagger has been the CEO of Bio-Gene Technology Limited (ASX:BGT) since 2018, and this article will examine the...